NCT01445262已完成不适用
Drug Use Investigation for XYZAL
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10,728
- 主要终点
- The number of adverse events in Japanese subjects treated with levocetirizine tablets
研究概览
简要总结
This post-marketing surveillance study (PMS) is conducted to collect safety and efficacy data among subjects with allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous who have never been treated with levocetirizine tablets before.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be the first time for taking levocetirizine tablet
排除标准
- •As this is PMS study, there are no exclusion criteria.
研究组 & 干预措施
Subjects prescribed levocetirizine tablets
Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
干预措施: Levocetirizine (Drug)
结局指标
主要结局
The number of adverse events in Japanese subjects treated with levocetirizine tablets
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Drug Use Investigation for PAXIL TabletMental DisordersNCT01371435GlaxoSmithKline3,708
已完成
不适用
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)Influenza, HumanNCT01390792GlaxoSmithKline622
已完成
不适用
Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or DysmenorrheaEndometriosis and DysmenorrheaNCT03126747Bayer715
已完成
不适用
YAZ Post-marketing Surveillance in JapanDysmenorrheaNCT01375998Bayer3,273
已完成
不适用
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism TreatmentAtaxiaNCT01428531GlaxoSmithKline200